Replies to post #250822 on Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

Thanks, but I wish I could have found more....I vaguely remember the topic coming up before. Needs more study.

[loanranger]

The Company made some safety-related comments in the PR issued the day after the MAKO slurfest.

Shorter: Inefficacy is not the only problem of Brilacidin. Incidence of sensory nerve symptoms, such as numbness and tingling of the extremities and elevated blood pressure due to unknown problems were reported as serious adverse events in 65-87% of Brilacidin-treated patients. This alone means that the drug is unlikely to get approved, in my view.

Cellceutix: 1) See above comments and link to presentation on Phase 2 data. 2) This is false. These were not reported as "serious adverse events in 65%-87%". In the recent phase 2b study, there were no "serious adverse events" (SAEs) related to either numbness/tingling or blood pressure.

While numbness/tingling were reported, it is not a safety concern. These cases were mild and transient, and the events fully resolved without any intervention -- similar to a Novocain injection by the dentist

http://www.ipharminc.com/press-release/2017/2/7/ieoasadelja0cm1122682nwus4f5n7